

## BIBLIOMETRIC ANALYSIS: CHEK2 GENE AND BREAST CANCER

N.V. Khudoyberdiyeva<sup>1,2</sup> M.M. Abdullayeva<sup>1</sup>

1. "National University of Uzbekistan"

2. ALFRAGANUS UNIVERSITY

### Abstract

Cancer has become one of the main problems for health organizations around the world. The risk of developing cancer during a lifetime (up to 75 years of age) is approximately 20%, and the risk of dying from cancer is 10% [1]. One in every five people will be diagnosed with cancer during their lifetime, and one out of ten patients with the disease will die from it. In 2020, 2.26 million new cases of cancer were reported [2]. Breast cancer is the most commonly diagnosed type of cancer in women worldwide and is the leading cause of death among women with the disease[3]. If the current trend in breast cancer continues, it is estimated that by 2040, over 3 million new cases and 1 million deaths will be recorded, solely due to population growth and aging. As of today, various levels of penetrant mutations associated with the risk of developing breast cancer, including mutations in the CHEK2 gene (checkpoint kinase gene), are known [4]. It has been determined that the CHEK2 gene is a susceptibility gene for breast cancer in several populations. In 2002, it was reported that a mutation in the CHEK2 gene could lead to the development of breast cancer, and numerous subsequent studies have confirmed this [5–7].

**Objective of the study:** A bibliometric analysis of articles published between 2018 and 2022 on the relationship between breast cancer and the CHEK2 gene.

**Materials and Methods:** The most highly cited articles on CHEK2 gene mutations were sourced from the Scopus database, with a total of 550 articles included. The results were analyzed using VOSviewer and other online bibliometric analysis platforms, with graphical analyses performed.

**Keywords:** CHEK2 gene, breast cancer, mutation.

**Results:** The number of published articles showed an increase mainly in the years 2018-2019 and 2020-2021. The majority of scientific research and publications were



conducted by scientific research institutions in the United States. [8]. The United Kingdom and Canada hold the next positions. This can be attributed to the fact that economically developed countries have the ability to allocate more funding for scientific research [9]. When relating our topic to the field of science, we can see that research is primarily linked to the medical field (49%). We conclude that this is due to the close connection of our topic to human health. The journal "Redox Biology" has published the highest number of articles on this subject. [10–13]. It should also be noted that the correlation between the journal's impact factor (IF) and the number of citations for articles is not particularly significant.

**Conclusion:** Recent research indicates that the CHEK2 gene plays a crucial role in the hereditary types of cancer development. Investigations in this area are increasing year by year. Studying mutations in the CHEK2 gene is essential not only for accurate diagnosis but also for selecting appropriate treatment methods for patients.

### References

1. Aleksakhina SN, Iyevleva AG, Sokolenko AP, et al. (2021) Loss of heterozygosity in CHEK2-associated breast cancer. *Voprosy Onkologii* 67: 658–664.
2. Agaoglu NB, Ng OH, Unal B, et al. (2022) Concurrent Pathogenic Variants of BRCA1, MUTYH and CHEK2 in a Hereditary Cancer Family. *Cancer Genetics* 268–269: 128–136.
3. Agiannitopoulos K, Papadopoulou E, Tsaousis GN, et al. (2019) Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: A case report. *BMC Medical Genetics* 20.
4. Ansari N, Shahrabi S, Khosravi A, et al. (2019) Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer. *Lab Medicine* 50: e36–e41.
5. Acevedo F, Deng Z, Armengol VD, et al. (2018) Managing Patient with Mutations in PALB2, CHEK2, or ATM. *Current Breast Cancer Reports* 10: 74–82.
6. Apostolou P, Dellatola V, Papadimitriou C, et al. (2021) Article chek2 pathogenic variants in greek breast cancer patients: Evidence for strong associations with estrogen receptor positivity, overuse of risk-reducing procedures and population founder effects. *Cancers* 13.



7. Apostolou P, Fostira F, Mollaki V, et al. (2018) Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients. *Journal of Human Genetics* 63: 877–886.
8. Ansari N, Shahrabi S, Khosravi A, et al. (2019) Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer. *Laboratory Medicine* 50: e36–e41.
9. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al. (2019) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. *JAMA Oncol* 5: 1749.
10. Delwiche FA (2018) Bibliometric Analysis of Scholarly Publications on the Zika Virus, 1952–2016. *Science & Technology Libraries* 37: 113–129.
11. Franco P, De Felice F, Jaggi R, et al. (2023) Breast cancer radiation therapy: A bibliometric analysis of the scientific literature. *Clinical and Translational Radiation Oncology* 39: 100556.
12. Fresno-Alba S, Denche-Zamorano Á, Pastor-Cisneros R, et al. (2023) Breast cancer and physical activity: A bibliometric analysis. *Front Oncol* 12: 1051482.
13. Gu J, Hu M, Chen Y, et al. (2023) Bibliometric analysis of global research on physical activity and sedentary behavior in the context of cancer. *Front Oncol* 13: 1095852.